CELLINK has been granted a patent for a unique technology enabling bioprinting in a clean environment. The patent protection applies to the Korean market, the company also conducts the process of expanding patent protection in additional countries.
The patent protection from the Korean Intellectual Property Office shows uniqueness and height of innovation. This technology is used in CELLINK’s flagship bioprinter the BIO X and the INKREDIBLE+ to enable true desktop printing and ensuring sterility during the printing process.
“We are extremely excited to have another granted patent for our revolutionary technology platform. As a globally recognized leader in the field, it is essential for us to protect our technologies so that we can continue to offer the most innovative solutions to our customers and collaborators around the world. The Clean Chamber Technology is a unique, value adding feature that ensures that the printing environment inside the Bioprinter is kept sterile so that the user can reduce the risk of contaminations and protect the precious cells during the printing process.”- Erik Gatenholm, CEO
The granted patent strengthens the company's protection for intellectual properties and is in line with the company's strategy to protect core technologies within the field. The company is in a phase where great focus is on the development of innovative solutions to enable printing of various tissues and organs.
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone: EU +46 73 267 00 00 Phone: +46 70 991 86 04
US +1 (650) 515 5566 US +1 (857) 332 2138
This information is such information as CELLINK AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on July 11, 2019 at. 11:50 CET.
CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at email@example.com.